The aim of this study is to systematically evaluate all available treatment options in chemotherapy-naive @entity1 with metastatic castration-resistant @entity263 (mCRPC). We systematically searched PubMed, EMBASE, and the Cochrane libraries up to 1 March 2016 for peer-reviewed publications on @entity922 ( @entity922 ). @entity922 were included if @entity1349 ( @entity1349 ), @entity1349 ( @entity1349 ), quality of life (QoL), or adverse events (AEs) were quantitatively evaluated. We assessed the risk of bias with the Cochrane Collaboration's tool and graded the evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group's approach. We included 25 articles, reporting on 10 unique @entity922 describing seven different comparisons. In one RCT, a prolonged @entity1349 and @entity1349 (high quality) were found with @entity17931 and @entity229 compared to placebo plus @entity229 . In one RCT, a prolonged @entity1349 and @entity1349 (high quality) were found with @entity14164 compared to placebo. In two @entity922 , a prolonged @entity1349 (high and moderate quality) was found with (223) @entity30365 compared to placebo, but its effect on @entity1349 is unknown. In three @entity922 , a prolonged @entity1349 (moderate quality) was found with sipuleucel-T compared to placebo, but no prolonged @entity1349 (low quality). In one RCT a prolonged @entity1349 (high quality) was found with orteronel compared to placebo, but no prolonged @entity1349 (moderate quality). In one RCT, a prolonged @entity1349 (moderate quality) was found with @entity12195 compared to placebo, but its effect on @entity1349 is unknown. In one RCT, a prolonged @entity1349 (high quality) was found with @entity14164 compared to @entity12195 , but its effect on @entity1349 is unknown. The best evidence was found for @entity17931 and @entity14164 for effective prolongation of @entity1349 and @entity1349 to treat chemotherapy-naive @entity1 with mCRPC. However, taking both QoL and AEs into consideration, other treatment modalities could be considered for individual @entity1 .

First-line non-cytotoxic therapy in chemotherapy-naive @entity1 with metastatic castration-resistant @entity263 : a systematic review of 10 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity17931 :: ('MESH:C089740', 'Chemical') :: ['abiraterone'] @entity30365 :: ('MESH:D011883', 'Chemical') :: ['radium'] @entity12195 :: ('MESH:C053541', 'Chemical') :: ['bicalutamide'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity14164 :: ('MESH:C540278', 'Chemical') :: ['enzalutamide'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'PFS', 'overall survival', 'progression-free survival'] @entity922 :: ('MESH:D013568', 'Disease') :: ['randomised clinical trials', 'RCTs']
@entity922 :: (MESH:D013568,Disease) :: ['randomised clinical trials']
